MyFinsight
Home
Blog
About
Contact
tgtx: the balance sheet
Download
Download image
Other current assets
$55,846K
Inventories
$146,953K
Accounts receivable, net
$265,384K
Short-term investment
securities
$57,501K
Cash and cash
equivalents
$74,081K
Other noncurrent
assets
$2,045K
Deferred tax assets
$366,627K
Right of use assets
$6,501K
Long-term investment
securities
$48,757K
Restricted cash
$1,329K
Total current assets
$599,765K
Total assets
$1,025,024K
Total liabilities and
stockholders equity
$1,025,024K
Total stockholders
equity
$607,218K
Total liabilities
$417,806K
Accumulated deficit
-$1,105,052K
Treasury stock, at cost,
3,543,643 and 367,903...
$100,234K
Additional paid-in capital
$1,812,345K
Lease liability
non-current
$7,308K
Loan payable
non-current
$245,340K
Deferred revenue,
non-current portion
$8,348K
Total current
liabilities
$156,810K
Common stock, 0.001 par
value per share...
$159K
Accrued compensation
$15,014K
Deferred revenue -
current portion
$26,399K
Lease liability
current portion
$1,068K
Other current
liabilities
$1,993K
Accounts payable and
accrued expenses
$112,336K
Back
Back
Balance Sheet
source: myfinsight.com
TG Therapeutics BRIUMVI Approval Call Slide Deck 12
TG THERAPEUTICS, INC. (TGTX)
TG Therapeutics BRIUMVI Approval Call Slide Deck 12
TG THERAPEUTICS, INC. (TGTX)